ptc is biopharmaceutical company focused on the discovery and development of orally-administered, proprietary small molecule drugs that target post-transcriptional control processes. while ptc’s discovery programs are directed at targets in multiple therapeutic areas, ptc is focusing particularly on the development and commercialization of treatments for orphan and ultra-orphan disorders. post-transcriptional control processes regulate the rate and timing of protein production and are essential to proper cellular function. ptc’s internally-discovered pipeline addresses multiple therapeutic areas, including neuromuscular disorders, oncology and infectious diseases. for more information on the company, please visit our website www.ptcbio.com.
Company profile
Ticker
PTCT
Exchange
Website
CEO
Stuart Peltz
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
PTC THERAPEUTICS INC
SEC CIK
Corporate docs
Subsidiaries
PTC Therapeutics International Limited • PTC Therapeutics GT, Inc. ...
IRS number
43416587
PTCT stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
29 Feb 24
8-K
Results of Operations and Financial Condition
29 Feb 24
8-K
CHMP Issues Negative Opinion for Renewal of Conditional Marketing Authorization for Translarna™ (ataluren) Following Re-examination Procedure
25 Jan 24
8-K
Results of Operations and Financial Condition
8 Jan 24
POSASR
Automatic shelf registration (post-effective amendment)
7 Nov 23
10-Q
2023 Q3
Quarterly report
26 Oct 23
8-K
Results of Operations and Financial Condition
26 Oct 23
8-K
Termination of a Material Definitive Agreement
19 Oct 23
8-K
PTC Therapeutics Announces Evrysdi® Royalty Agreement with Royalty Pharma for Up To $1.5 Billion
19 Oct 23
8-K
PTC Announces Further Strategic Prioritization and Associated Reduction in Workforce
28 Sep 23
Transcripts
PTCT
Earnings call transcript
2023 Q4
29 Feb 24
PTCT
Earnings call transcript
2023 Q3
26 Oct 23
PTCT
Earnings call transcript
2023 Q2
3 Aug 23
PTCT
Earnings call transcript
2023 Q1
27 Apr 23
PTCT
Earnings call transcript
2022 Q4
21 Feb 23
PTCT
Earnings call transcript
2022 Q3
27 Oct 22
PTCT
Earnings call transcript
2022 Q2
7 Aug 22
PTCT
Earnings call transcript
2022 Q1
4 May 22
PTCT
Earnings call transcript
2021 Q4
23 Feb 22
PTCT
Earnings call transcript
2021 Q3
29 Oct 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 181.41 mm | 181.41 mm | 181.41 mm | 181.41 mm | 181.41 mm | 181.41 mm |
Cash burn (monthly) | 14.36 mm | (no burn) | 55.53 mm | 61.62 mm | 4.84 mm | 18.67 mm |
Cash used (since last report) | 85.95 mm | n/a | 332.34 mm | 368.77 mm | 28.96 mm | 111.76 mm |
Cash remaining | 95.46 mm | n/a | -150.93 mm | -187.36 mm | 152.45 mm | 69.65 mm |
Runway (months of cash) | 6.6 | n/a | -2.7 | -3.0 | 31.5 | 3.7 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 548 |
Opened positions | 74 |
Closed positions | 54 |
Increased positions | 224 |
Reduced positions | 168 |
13F shares | Current |
---|---|
Total value | 15.49 tn |
Total shares | 116.51 mm |
Total puts | 174.30 k |
Total calls | 354.00 k |
Total put/call ratio | 0.5 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 13.87 mm | $1.97 tn |
BLK Blackrock | 10.85 mm | $1.54 tn |
T. Rowe Price Investment Management | 9.18 mm | $1.31 tn |
ROK Rockwell Automation | 5.91 mm | $861.87 mm |
Pictet Asset Management Holding | 4.88 mm | $691.60 bn |
STT State Street | 4.58 mm | $648.81 bn |
Lone Pine Capital | 3.17 mm | $448.62 bn |
Select Equity | 2.93 mm | $414.64 bn |
Geode Capital Management | 2.70 mm | $381.30 bn |
Alliancebernstein | 2.66 mm | $376.54 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Feb 24 | Utter Christine Marie | Common Stock | Grant | Acquire A | No | No | 0 | 2,900 | 0.00 | 52,428 |
15 Feb 24 | Utter Christine Marie | Common Stock | Grant | Acquire A | No | No | 0 | 14,000 | 0.00 | 49,528 |
15 Feb 24 | Utter Christine Marie | Stock Option Common Stock | Grant | Acquire A | No | No | 25.69 | 35,000 | 899.15 k | 35,000 |
15 Feb 24 | Neil Gregory Almstead | Common Stock | Grant | Acquire A | Yes | No | 0 | 870 | 0.00 | 4,576 |
15 Feb 24 | Neil Gregory Almstead | Common Stock | Grant | Acquire A | No | No | 0 | 6,000 | 0.00 | 86,202 |
15 Feb 24 | Neil Gregory Almstead | Common Stock | Grant | Acquire A | No | No | 0 | 19,000 | 0.00 | 80,202 |
15 Feb 24 | Neil Gregory Almstead | Stock Option Common Stock | Grant | Acquire A | No | No | 25.69 | 47,500 | 1.22 mm | 47,500 |
15 Feb 24 | Eric Pauwels | Common Stock | Grant | Acquire A | No | No | 0 | 2,300 | 0.00 | 68,481 |
15 Feb 24 | Eric Pauwels | Common Stock | Grant | Acquire A | No | No | 0 | 22,000 | 0.00 | 66,181 |
15 Feb 24 | Eric Pauwels | Stock Option Common Stock | Grant | Acquire A | No | No | 25.69 | 55,000 | 1.41 mm | 55,000 |
News
PTC Therapeutics Submits Sepiapterin MAA For Treatment Of PKU To EMA
28 Mar 24
RBC Capital Reiterates Sector Perform on PTC Therapeutics, Maintains $28 Price Target
8 Mar 24
Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday
1 Mar 24
RBC Capital Maintains Sector Perform on PTC Therapeutics, Raises Price Target to $28
1 Mar 24
Cantor Fitzgerald Reiterates Overweight on PTC Therapeutics, Maintains $45 Price Target
1 Mar 24
Press releases
PTC Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA
28 Mar 24
PTC Therapeutics Provides Key Regulatory Updates
19 Mar 24
PTC Therapeutics to Participate at Upcoming Investor Conferences
27 Feb 24
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
22 Feb 24
PTCT ALERT: Johnson Fistel Encourages Investors to Inquire About PTC Therapeutics Securities Class Action Investigation
25 Jan 24